UCSD Health Sciences - Movement Disorders Center
Welcome,         Profile    Billing    Logout  
 7 Trials 
13 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Litvan, Irene
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Active, not recruiting
2
160
Europe, US
Neflamapimod, VX-745, Placebo
EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc
Dementia With Lewy Bodies
08/24
03/25
4RTNI-2, NCT02966145: 4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

Active, not recruiting
N/A
232
Canada, US
Observational Study
University of California, San Francisco, National Institutes of Health (NIH), National Institute on Aging (NIA)
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
12/24
12/24
PDGENE, NCT04057794: PDGeneration: Mapping the Future of Parkinson's Disease

Active, not recruiting
N/A
1982
US
Lab Assay for seven genetic variants for Parkinson's Disease
Parkinson's Foundation, Fulgent Laboratories, Indiana University, The Parkinson Study Group, Navitas Clinical Research, Inc
Parkinson's Disease and Parkinsonism
12/21
04/25
NCT04363684: ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Recruiting
N/A
2100
Canada, US
Mayo Clinic, University of California, San Francisco, National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS)
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
06/25
06/25
NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry

Recruiting
N/A
25000
Canada, US, RoW
Lab Assay for seven genetic variants for Parkinson's Disease
Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group
Parkinson's Disease
12/24
06/25
NCT04735627: Real-Time Levodopa Level Monitoring in Parkinson Disease

Recruiting
N/A
20
US
Levodopameter
University of California, San Diego
Parkinson Disease
12/27
02/28
Shprecher, David
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia with Lewy Bodies
11/24
11/24
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Active, not recruiting
2
160
Europe, US
Neflamapimod, VX-745, Placebo
EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc
Dementia With Lewy Bodies
08/24
03/25
LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort

Recruiting
N/A
4500
Europe, Canada, US, RoW
Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders
Parkinson Disease
12/33
12/33
Hernandez, Jasmin
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting
3
102
Europe, Canada, US, RoW
Ampreloxetine, TD-9855, Placebo
Theravance Biopharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
12/24
01/27
EIP21-NFD-504, NCT05869669: RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Active, not recruiting
2
160
Europe, US
Neflamapimod, VX-745, Placebo
EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc
Dementia With Lewy Bodies
08/24
03/25

Download Options